BE OPTIMAL: BKZ in PsA Phase 3 RCT
Data at 52 wks 700+ completed study
ACR50: 53% PBO/BKZ, 54% BKZ, 50% ADA
PASI 100 65% PBO/BKZ, 61% BKZ, 48% ADA
No Rx progression 87% PBO/BKZ, 89% BKZ, 94% ADA
Candida infections 7% BKZ, 0.7% ADA
https://t.co/MMjN1Aa3qf
Abs#L02 #ACR22 @Rheumnow https://t.co/keF0QOZMwA
Links:
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Ar…
http://bit.ly/3O4C0cK
14-11-2022